An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation

NCT06466486 | Terminated Phase 1

• 2 other identifiers: 0004262023-507630-25-00
• Study Type: interventional
• Target: 310
• Locations: 5 countries
• Sites: 15

Brief Summary

This is a phase 1b clinical trial with Choriogonadotropin beta (FE999302) and Follitropin delta (Rekovelle). The trial is multicentre, randomized, partially double-blind, placebo-controlled, parallel-group investigating the effect of FE999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin. The primary endpoint is the number of good-quality blastocysts on day 5 after oocyte retrieval. Secondary endpoints are number of follicles by size category and serum concentration of different hormones on stimulation day 6 and end-of stimulation, the number of stimulation days and oocytes retrieved, the number of metaphase II oocytes and fertilised oocytes, number of blastocysts on day 5, number of cryopreserved blastocysts, endometrial thickness at eos, positive bhcg rate, clinical pregnancy, vital pregnancy and ongoing pregnancy.

Conditions

Fertility

Outcome Measures

Primary Outcomes (1)

• Number of good-quality blastocysts

  The number of good-quality blastocysts

  Day 5 after oocyte retrieval.

Secondary Outcomes (14)

• Number and size of follicles

  On stimulation day 6 and up to 20 days

• Serum hormone concentrations

  On stimulation day 6, and up to 20 days

• Serum hormone concentrations

  Up to 22 days

• Number of Stimulation days

  Up to 20 days

• Number of oocytes

  Up to 22 days

Study Arms (6)

Placebo

PLACEBO COMPARATOR

Follitropin delta and FE 999302 placebo

Drug: Follitropin delta; Drug: FE999302 Placebo

FE999302 and Placebo Every 2nd Day Group

ACTIVE COMPARATOR

Follitropin delta and FE 999302 every 2nd day and FE 999302 placebo every 2nd day

Drug: Follitropin delta; Drug: FE999302; Drug: FE999302 Placebo

FE999302 Dose Group 1

ACTIVE COMPARATOR

Follitropin delta and FE 999302

Drug: Follitropin delta; Drug: FE999302

FE999302 Dose Group 2

ACTIVE COMPARATOR

Follitropin delta and FE 999302

Drug: Follitropin delta; Drug: FE999302

Placebo Group 2

PLACEBO COMPARATOR

Follitropin delta and FE 999302 placebo

Drug: Follitropin delta; Drug: FE999302 Placebo

FE999302 Dose Group 3

ACTIVE COMPARATOR

Follitropin delta and FE 999302

Drug: Follitropin delta; Drug: FE999302

Interventions

FE999302 DRUG

To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

FE999302 Dose Group 1; FE999302 Dose Group 2; FE999302 Dose Group 3; FE999302 and Placebo Every 2nd Day Group

FE999302 Placebo DRUG

To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

FE999302 and Placebo Every 2nd Day Group; Placebo; Placebo Group 2

Follitropin delta DRUG

The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

Also known as: REKOVELLE

FE999302 Dose Group 1; FE999302 Dose Group 2; FE999302 Dose Group 3; FE999302 and Placebo Every 2nd Day Group; Placebo; Placebo Group 2

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subject informed consent form signed before any trial-related activities.
• In good physical and mental health as judged by the investigator.
• Serum anti-Müllerian hormone (AMH) levels of 15.0-35.0 pmol/L at screening (measured at central laboratory).
• Pre-menopausal women between the ages of 18 and 40 years. The subjects must be at least 18 years (including the 18th birthday) and no more than 40 years (up to the day before the 41st birthday) when they sign the informed consent(s).
• Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor.
• Infertility for at least 1 year before screening for subjects \<35 years or for at least 6 months for subjects ≥35 years (not applicable in case of tubal or severe male factor infertility).

You may not qualify if:

• Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory.
• Early follicular phase (cycle day 2-5) serum levels of follicle-stimulating hormone (FSH) between 1 and 15 IU/L (measured at central laboratory).
• Body mass index (BMI) between 18.0 and 30.0 kg/m2 (both inclusive) at screening.
• Known polycystic ovary syndrome (PCOS) or known endometriosis stage III-IV (American Society for Reproductive Medicine, 2012).
• Poor response in a previous controlled ovarian stimulation cycle using a gonadotropin starting dose of 150 IU/day or higher. Poor response is defined as \<4 oocytes retrieved, or cycle cancellation before oocyte retrieval due to inadequate follicular development.
• Excessive ovarian response in a previous controlled ovarian stimulation cycle for IVF/ICSI using a daily FSH/ human menopausal gonadotropin (hMG) dose of ≤225 IU, defined as ≥25 oocytes retrieved or cycle cancellation before oocyte retrieval due to excessive ovarian response, including risk of ovarian hyperstimulation syndrome (OHSS).
• One or more follicles ≥10 mm (including cysts) observed on the transvaginal ultrasound before randomisation on stimulation day 1 (puncture of cysts is allowed before randomisation).
• Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy \[excluding ectopic pregnancy\] and before week 24 of pregnancy).
• Any known clinically significant systemic disease (e.g. insulin-dependent diabetes).
• Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver, or kidney) with the exception of controlled thyroid function disease.
• Known tumours of the ovary, breast, uterus, adrenal gland, pituitary, or hypothalamus which would contraindicate the use of gonadotropins.
• Any abnormal finding of clinical chemistry and haematology at screening or vital signs at randomisation, which is judged clinically relevant by the investigator and/or requires intervention.
• Currently breast-feeding.
• Undiagnosed vaginal bleeding.
• Findings at the gynaecological examination at screening which preclude gonadotropin stimulation or are associated with a reduced chance of pregnancy, e.g. congenital uterine abnormalities or retained intrauterine device.

Sponsors & Collaborators

• Ferring Pharmaceuticals: lead

Study Sites (15)

Ferring Investigational Site

Brussels, 1090, Belgium

Location

Ferring Investigational Site

Edegem, 2650, Belgium

Location

Ferring Investigational Site

Prague, Prague, 150 00, Czechia

Location

Ferring Investigational Site

Prague, 160 00, Czechia

Location

Ferring Investigational Site

Prague, 184 00, Czechia

Location

Ferring Investigational Site

Hvidovre, Hvidovre, 2650, Denmark

Location

Ferring Investigational Site

Copenhagen, 2100, Denmark

Location

Ferring Investigational Site

Trondheim, Sor-Trondelag, 7042, Norway

Location

Ferring Investigational Site

Bergen, 5006, Norway

Location

Ferring Investigational Site

Porsgrunn, 3913, Norway

Location

Ferring Investigational Site

Madrid, Aravaca, 28023, Spain

Location

Ferring Investigational Site

Barcelona, 08028, Spain

Location

Ferring Investigational Site

Madrid, 28010, Spain

Location

Ferring Investigational Site

Seville, 41092, Spain

Location

Ferring Investigational Site

Valencia, 46015, Spain

Location

MeSH Terms

Interventions

follitropin delta

Study Officials

• Global Clinical Compliance

  Ferring Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 29, 2024
• First Posted: June 20, 2024
• Study Start: June 14, 2024
• Primary Completion: December 3, 2025
• Study Completion: December 3, 2025
• Last Updated: March 30, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

ES (5); DK (2); BE (2); NO (3); CZ (3)